In Vitro Activities of LTX-109, a Synthetic Antimicrobial Peptide, against Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, Daptomycin-Nonsusceptible, and Linezolid-Nonsusceptible Staphylococcus aureus ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Saravolatz, L. D., Pawlak, J., Johnson, L., Bonilla, H., Saravolatz, L. D., Fakih, M. G., Fugelli, A., Olsen, W. 2012; 56 (8): 4478–82

Abstract

LTX-109 and eight other antimicrobial agents were evaluated against 155 methicillin-resistant Staphylococcus aureus (MRSA) isolates, including strains resistant to vancomycin and strains with decreased susceptibility to daptomycin and linezolid, by microdilution tests to determine MICs. Time-kill assays were performed against representative MRSA, vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant S. aureus (VRSA) isolates. LTX-109 demonstrated a MIC range of 2 to 4 µg/ml and dose-dependent rapid bactericidal activity against S. aureus. This activity was not influenced by resistance to other antistaphylococcal agents.

View details for DOI 10.1128/AAC.00194-12

View details for Web of Science ID 000306826300058

View details for PubMedID 22585222

View details for PubMedCentralID PMC3421571